# Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

> **NCT05161533** · PHASE2 · WITHDRAWN · sponsor: **University of Washington**

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Etoposide
- **RADIATION:** Hypofractionated Radiation Therapy
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05161533
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-19
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161533, "Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05161533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*